Regulation of aldosterone secretion: From physiology to disease

European Journal of Endocrinology

Volumn 168, Issue 6, 2013, Pages

  Beuschlein, Felix ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ADENOSINE TRIPHOSPHATE; ADENOSINE TRIPHOSPHATE 1A1; ADENOSINE TRIPHOSPHATE 2B3; ALDOSTERONE; ALDOSTERONE SYNTHASE; ANGIOTENSIN 1B RECEPTOR; ANGIOTENSIN II; ANTIHYPERTENSIVE AGENT; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE; CALMODULIN; CHOLESTEROL; CORTICOTROPIN; CRYPTOCHROME; DEOXYCORTICOSTERONE; MINERALOCORTICOID ANTAGONIST; OSTEOPONTIN; POTASSIUM CHANNEL; PROTEIN KCNJ5; STEROIDOGENIC ACUTE REGULATORY PROTEIN; UNCLASSIFIED DRUG;

ADRENAL CORTEX ADENOMA; ADRENALECTOMY; ALDOSTERONE BLOOD LEVEL; ALDOSTERONE RELEASE; BLOOD PRESSURE REGULATION; CALCIUM TRANSPORT; CARDIOVASCULAR RISK; CIRCADIAN RHYTHM; CRY GENE; DIASTOLIC BLOOD PRESSURE; DISEASE REGISTRY; ENZYME REGULATION; EPIGENETICS; EXOME; FAMILIAL HYPERALDOSTERONISM TYPE 1; FLUORESCENCE ANALYSIS; GENE; GENE EXPRESSION; GENE IDENTIFICATION; GENE LOCUS; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HIGH THROUGHPUT SEQUENCING; HISTOPATHOLOGY; HORMONAL REGULATION; HORMONE DETERMINATION; HORMONE SYNTHESIS; HUMAN; HYPERALDOSTERONISM; HYPERTENSION; HYPOKALEMIA; HYPOKALEMIC PRIMARY HYPERALDOSTERONISM; IDIOPATHIC DISEASE; IN VITRO STUDY; IN VIVO STUDY; INVASIVE PROCEDURE; MUTAGENESIS; MUTATIONAL ANALYSIS; NONHUMAN; PATHOPHYSIOLOGY; PHENOTYPE; POTASSIUM BLOOD LEVEL; PREDICTION; PREVALENCE; PRIMARY HYPERALDOSTERONISM; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROTEIN FUNCTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; STEROIDOGENESIS; SYSTOLIC BLOOD PRESSURE; TANDEM MASS SPECTROMETRY; TRANSCRIPTION INITIATION;

ADENOMA; ALDOSTERONE; ANIMALS; G PROTEIN-COUPLED INWARDLY-RECTIFYING POTASSIUM CHANNELS; GENOME-WIDE ASSOCIATION STUDY; HUMANS; HYPERALDOSTERONISM; MICE; MODELS, BIOLOGICAL; SODIUM-POTASSIUM-EXCHANGING ATPASE;

EID: 84878682776     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-13-0263     Document Type: Review

References (89)

1. Egan BM, Zhao Y & Axon RN. US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. Journal of the American Medical Association 2010 303 2043-2050. (doi:10.1001/jama.2010.650)
2. Labeit AM, Klotsche J, Pieper L, Pittrow D, Einsle F, Stalla GK, Lehnert H, Silber S, Zeiher AM, Marz W et al. Changes in the prevalence, treatment and control of hypertension in Germany? A clinical-epidemiological study of 50.000 primary care patients PLoS ONE 2012 7 e52229. (doi:10.1371/journal.pone.0052229)
3. Ferrario CM. Role of angiotensin II in cardiovascular disease therapeutic implications of more than a century of research. Journal of Renin-Angiotensin-Aldosterone System 2006 7 3-14. (doi:10.3317/jraas.2006.003) (Pubitemid 43891239)
4. Brewster UC, Setaro JF & Perazella MA. The renin-angiotensin- aldosterone system: cardiorenal effects and implications for renal and cardiovascular disease states. American Journal of the Medical Sciences 2003 326 15-24. (doi:10.1097/00000441-200307000-00003) (Pubitemid 36870293)
5. Cooper ME. The role of the renin-angiotensin-aldosterone system in diabetes and its vascular complications. American Journal of Hypertension 2004 17 16S-20S quiz (A12-A14). (doi:10.1016/j.amjhyper.2004.08.004) (Pubitemid 39469911)
6. Vasan RS, Evans JC, Larson MG, Wilson PW, Meigs JB, Rifai N, Benjamin EJ & Levy D. Serum aldosterone and the incidence of hypertension in nonhypertensive persons. New England Journal of Medicine 2004 351 33-41. (doi:10.1056/NEJMoa033263) (Pubitemid 38857245)
7. Tsutamoto T, Sakai H, Tanaka T, Fujii M, Yamamoto T, Wada A, Ohnishi M & Horie M. Comparison of active renin concentration and plasma renin activity as a prognostic predictor in patients with heart failure. Circulation Journal 2007 71 915-921. (doi:10.1253/circj.71.915) (Pubitemid 46833931)
8. Guder G, Bauersachs J, Frantz S, Weismann D, Allolio B, Ertl G, Angermann CE & Stork S. Complementary and incremental mortality risk prediction by cortisol and aldosterone in chronic heart failure. Circulation 2007 115 1754-1761. (doi:10.1161/CIRCULATIONAHA.106.653964) (Pubitemid 46648612)
9. Beygui F, Collet JP, Benoliel JJ, Vignolles N, Dumaine R, Barthelemy O & Montalescot G. High plasma aldosterone levels on admission are associated with death in patients presenting with acute ST-elevation myocardial infarction. Circulation 2006 114 2604-2610. (doi:10.1161/CIRCULATIONAHA.106.634626) (Pubitemid 44967343)
10. Tylicki L, Larczynski W & Rutkowski B. Renal protective effects of the renin-angiotensin-aldosterone system blockade: from evidence-based approach to perspectives. Kidney & Blood Pressure Research 2005 28 230-242. (doi:10.1159/000087842) (Pubitemid 43048613)
11. HannemannA, FriedrichN, Ludemann J, Volzke H, Rettig R, Peters J, Reincke M, Doring A, Nauck M & Wallaschofski H. Reference intervals for aldosterone, renin, and the aldosterone-to-renin ratio in the population-based Study of Health in Pomerania (SHIP-1). Hormone and Metabolic Research 2010 42 392-399. (doi:10.1055/s-0030-1247545)
12. Calhoun DA, Nishizaka MK, Zaman MA, Thakkar RB & Weissmann P. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension 2002 40 892-896. (doi:10.1161/01.HYP.0000040261.30455.B6) (Pubitemid 35434912)
13. Douma S, Petidis K, Doumas M, Papaefthimiou P, Triantafyllou A, Kartali N, Papadopoulos N, Vogiatzis K & Zamboulis C. Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study. Lancet 2008 371 1921-1926. (doi:10.1016/S0140-6736(08)60834-X) (Pubitemid 351778191)
14. Funder JW & Reincke M. Aldosterone: a cardiovascular risk factor? Biochimica et Biophysica Acta 2010 1802 1188-1192. (doi:10.1016/j.bbadis.2010. 08.005)
15. Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME & Mourad JJ. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. Journal of the American College of Cardiology 2005 45 1243-1248. (doi:10.1016/j.jacc.2005.01.015) (Pubitemid 40523144)
16. Catena C, Colussi G, Nadalini E, Chiuch A, Baroselli S, Lapenna R & Sechi LA. Cardiovascular outcomes in patients with primary aldosteronism after treatment. Archives of Internal Medicine 2008 168 80-85. (doi:10.1001/ archinternmed.2007.33)
17. Sechi LA, Colussi G, Di Fabio A & Catena C. Cardiovascular and renal damage in primary aldosteronism: outcomes after treatment. American Journal of Hypertension 2010 23 1253-1260. (doi:10.1038/ajh.2010.169)
18. Rossi GP, Bernini G, Desideri G, Fabris B, Ferri C, Giacchetti G, Letizia C, Maccario M, Mannelli M, Matterello MJ et al. Renal damage in primary aldosteronism: results of the PAPY Study. Hypertension 2006 48 232-238. (doi:10.1161/01.HYP.0000230444.01215.6a) (Pubitemid 44309817)
19. Funder J, Carey R, Fardella C, Gomez-Sanchez C, Mantero F, Stowasser M, Young W & Montori VM. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an Endocrine Society Clinical Practice Guideline. European Journal of Endocrinology 2009 93 3266-3281. (doi:10.1530/EJE-09-0870)
20. Rossi GP, Barisa M, Allolio B, Auchus RJ, Amar L, Cohen D, Degenhart C, Deinum J, Fischer E, Gordon R et al. The Adrenal Vein Sampling International Study (AVIS) for identifying the major subtypes of primary aldosteronism. Journal of Clinical Endocrinology and Metabolism 2012 97 1606-1614. (doi:10.1210/jc.2011-2830)
21. Stewart PM & Allolio B. Adrenal vein sampling for primary aldosteronism: time for a reality check. Clinical Endocrinology 2010 72 146-148. (doi:10.1111/j.1365-2265.2009.03714.x)
22. Gomez-Sanchez CE, Rossi GP, Fallo F & Mannelli M. Progress in primary aldosteronism: present challenges and perspectives. Hormone and Metabolic Research 2010 42 374-381. (doi:10.1055/s-0029-1243619)
23. Boulkroun S, Samson-Couterie B, Dzib JF, Lefebvre H, Louiset E, Amar L, Plouin PF, Lalli E, Jeunemaitre X, Benecke A et al. Adrenal cortex remodeling and functional zona glomerulosa hyperplasia in primary aldosteronism. Hypertension 2010 56 885-892. (doi:10.1161/HYPERTENSIONAHA.110.158543)
24. Manolopoulou J, Bielohuby M, Caton SJ, Gomez-Sanchez CE, Renner-Mueller I, Wolf E, Lichtenauer UD, Beuschlein F, Hoeflich A & Bidlingmaier M. A highly sensitive immunofluorometric assay for the measurement of aldosterone in small sample volumes: validation in mouse serum. Journal of Endocrinology 2008 196 215-224. (doi:10.1677/JOE-07-0134) (Pubitemid 351298507)
25. Sun M, Manolopoulou J, Spyroglou A, Beuschlein F, Hantel C, Wu Z, Bielohuby M, Hoeflich A, Liu C & Bidlingmaier M. A microsphere-based duplex competitive immunoassay for the simultaneous measurements of aldosterone and testosterone in small sample volumes: validation in human and mouse plasma. Steroids 2010 75 1089-1096. (doi:10.1016/j.steroids.2010.07.005)
26. Johnsen IK, Slawik M, Shapiro I, Hartmann MF, Wudy SA, Looyenga BD, Hammer GD, Reincke M & Beuschlein F. Gonadectomy in mice of the inbred strain CE/J induces proliferation of sub-capsular adrenal cells expressing gonadal marker genes. Journal of Endocrinology 2006 190 47-57. (doi:10.1677/joe.1.06750) (Pubitemid 44161061)
27. Haller F, Prehn C & Adamski J. Quantification of steroids in human and mouse plasma using online solid phase extraction coupled to liquid chromatography tandem mass spectrometry. Nature 2010. (doi:10.1038/nprot.2010. 22)
28. Spyroglou A, Sabrautzki S, Rathkolb B, Bozoglu T, Hrabe de Angelis M, Reincke M, Bidlingmaier M & Beuschlein F. Gender, strain and inheritance dependent variation in aldosterone secretion in mice. Journal of Endocrinology 2012 215 375-381. (doi:10.1530/JOE-12-0429)
29. Bogdarina I, Welham S, King PJ, Burns SP & Clark AJ. Epigenetic modification of the renin-angiotensin system in the fetal programming of hypertension. Circulation Research 2007 100 520-526. (doi:10.1161/01.RES. 0000258855.60637.58) (Pubitemid 46673261)
30. Bassett MH,White PC & Rainey WE. The regulation of aldosterone synthase expression. Molecular and Cellular Endocrinology 2004 217 67-74. (doi:10.1016/j.mce.2003.10.011) (Pubitemid 38596630)
31. Christenson LK & Strauss JF III. Steroidogenic acute regulatory protein: an update on its regulation and mechanism of action. Archives of Medical Research 2001 32 576-586. (doi:10.1016/S0188-4409(01)00338-1) (Pubitemid 34031750)
32. Lin D, Sugawara T, Strauss JF III, Clark BJ, Stocco DM, Saenger P, Rogol A & Miller WL. Role of steroidogenic acute regulatory protein in adrenal and gonadal steroidogenesis. Science 1995 267 1828-1831. (doi:10.1126/science. 7892608)
33. Cherradi N, Brandenburger Y & Capponi AM. Mitochondrial regulation of mineralocorticoid biosynthesis by calcium and the StAR protein. European Journal of Endocrinology 1998 139 249-256. (doi:10.1530/eje.0.1390249) (Pubitemid 28430532)
34. Curnow KM, Tusie-Luna MT, Pascoe L, Natarajan R, Gu JL, Nadler JL & White PC. The product of the CYP11B2 gene is required for aldosterone biosynthesis in the human adrenal cortex. Molecular Endocrinology 1991 5 1513-1522. (doi:10.1210/mend-5-10-1513)
35. Boyd JE & Mulrow PJ. Further studies of the influence of potassium upon aldosterone production in the rat. Endocrinology 1972 90 299-301. (doi:10.1210/endo-90-1-299)
36. Varnai P, Petheo GL, Makara JK & Spat A. Electrophysiological study on the high KC sensitivity of rat glomerulosa cells. Pflügers Archiv: European Journal of Physiology 1998 435 429-431. (doi:10.1007/s004240050534) (Pubitemid 28066237)
37. Akizuki O, Inayoshi A, Kitayama T, Yao K, Shirakura S, Sasaki K, Kusaka H & Matsubara M. Blockade of T-type voltage-dependent Ca2C channels by benidipine, a dihydropyridine calcium channel blocker, inhibits aldosterone production in human adrenocortical cell line NCI-H295R. European Journal of Pharmacology 2008 584 424-434. (doi:10.1016/j.ejphar.2008.02.001)
38. Lotshaw DP. Role of membrane depolarization and T-type Ca2C channels in angiotensin II and KC stimulated aldosterone secretion. Molecular and Cellular Endocrinology 2001 175 157-171. (doi:10.1016/S0303-7207(01)00384-7) (Pubitemid 32372552)
39. Condon JC, Pezzi V, Drummond BM, Yin S & Rainey WE. Calmodulin-dependent kinase I regulates adrenal cell expression of aldosterone synthase. Endocrinology 2002 143 3651-3657. (doi:10.1210/en.2001-211359) (Pubitemid 34925742)
40. Bassett MH, Suzuki T, Sasano H, White PC & Rainey WE. The orphan nuclear receptors NURR1 and NGFIB regulate adrenal aldosterone production. Molecular Endocrinology 2004 18 279-290. (doi:10.1210/me.2003-0005) (Pubitemid 38183928)
41. Clyne CD, Zhang Y, Slutsker L, Mathis JM,White PC & Rainey WE. Angiotensin II and potassium regulate human CYP11B2 transcription through common cis-elements. Molecular Endocrinology 1997 11 638-649. (doi:10.1210/me.11.5. 638) (Pubitemid 27193799)
42. Denner K, Rainey WE, Pezzi V, Bird IM, Bernhardt R & Mathis JM. Differential regulation of 11β-hydroxylase and aldosterone synthase in human adrenocortical H295R cells. Molecular and Cellular Endocrinology 1996 121 87-91. (doi:10.1016/0303-7207(96)03853-1) (Pubitemid 26268056)
43. Spyroglou A, Manolopoulou J, Wagner S, Bidlingmaier M, Reincke M & Beuschlein F. Short term regulation of aldosterone secretion after stimulation and suppression experiments in mice. Journal of Molecular Endocrinology 2009 42 407-413. (doi:10.1677/JME-08-0167)
44. Sackmann S, Lichtenauer U, Shapiro I, Reincke M & Beuschlein F. Aldosterone producing adrenal adenomas are characterized by activation of calcium/calmodulin-dependent protein kinase (CaMK) dependent pathways. Hormone and Metabolic Research 2011 43 106-111. (doi:10.1055/s-0030-1269899)
45. Dierks A, Lichtenauer UD, Sackmann S, Spyroglou A, Shapiro I, Geyer M, Manonopoulou J, Reincke M, Hantel C & Beuschlein F. Identification of adrenal genes regulated in a potassiumdependent manner. Journal of Molecular Endocrinology 2010 45 193-206. (doi:10.1677/JME-09-0171)
46. Xing Y, Nakamura Y & Rainey WE. G protein-coupled receptor expression in the adult and fetal adrenal glands. Molecular and Cellular Endocrinology 2009 300 43-50. (doi:10.1016/j.mce.2008.10.036)
47. Marques FZ, Campain AE, Yang YH & Morris BJ. Meta-analysis of genome-wide gene expression differences in onset and maintenance phases of genetic hypertension. Hypertension 2010 56 319-324. (doi:10.1161/ HYPERTENSIONAHA.110.155366)
48. Spat A & Hunyady L. Control of aldosterone secretion: a model for convergence in cellular signaling pathways. Physiological Reviews 2004 84 489-539. (doi:10.1152/physrev.00030.2003) (Pubitemid 38365491)
49. Heitzmann D, Derand R, Jungbauer S, Bandulik S, Sterner C, Schweda F, ElWakil A, Lalli E, Guy N, Mengual R et al. Invalidation of TASK1 potassium channels disrupts adrenal gland zonation and mineralocorticoid homeostasis. EMBO Journal 2008 27 179-187. (doi:10.1038/sj.emboj.7601934)
50. Davies LA, Hu C, Guagliardo NA, Sen N, Chen X, Talley EM, Carey RM, Bayliss DA & Barrett PQ. TASK channel deletion in mice causes primary hyperaldosteronism. PNAS 2008 105 2203-2208. (doi:10.1073/pnas.0712000105) (Pubitemid 351439489)
51. Guagliardo NA, Yao J, Hu C, Schertz EM, Tyson DA, Carey RM, Bayliss DA & Barrett PQ. TASK-3 channel deletion in mice recapitulates low-renin essential hypertension. Hypertension 2012 59 999-1005. (doi:10.1161/ HYPERTENSIONAHA.111.189662)
52. Penton D, Bandulik S, Schweda F, Haubs S, Tauber P, Reichold M, Cong LD, El Wakil A, Budde T, Lesage F et al. Task3 potassium channel gene invalidation causes low renin and salt-sensitive arterial hypertension. Endocrinology 2012 153 4740-4748. (doi:10.1210/en.2012-1527)
53. Doi M, Takahashi Y, Komatsu R, Yamazaki F, Yamada H, Haraguchi S, Emoto N, Okuno Y, Tsujimoto G, Kanematsu A et al. Salt-sensitive hypertension in circadian clock-deficient Cry-null mice involves dysregulated adrenal Hsd3b6. Nature Medicine 2010 16 67-74. (doi:10.1038/nm.2061)
54. Rakova N, Juttner K, Dahlmann A, Schroder A, Linz P, Kopp C, Rauh M, Goller U, Beck L, Agureev A et al. Long-term space flight simulation reveals infradian rhythmicity in human Na(C) balance. Cell Metabolism 2013 17 125-131. (doi:10.1016/j.cmet.2012.11.013)
55. Clark AT, Goldowitz D, Takahashi JS, Vitaterna MH, Siepka SM, Peters LL, Frankel WN, Carlson GA, Rossant J, Nadeau JH et al. Implementing large-scale ENU mutagenesis screens in North America. Genetica 2004 122 51-64. (doi:10.1007/s10709-004-1436-6) (Pubitemid 39459524)
56. Rinchik EM. Chemical mutagenesis and fine-structure functional analysis of the mouse genome. Trends in Genetics 1991 7 15-21. (doi:10.1016/0168-9525(91) 90016-J) (Pubitemid 121001896)
57. Noveroske JK, Weber JS & Justice MJ. The mutagenic action of N-ethyl-N-nitrosourea in the mouse. Mammalian Genome 2000 11 478-483. (doi:10.1007/s003350010093) (Pubitemid 30602210)
58. Justice MJ, Carpenter DA, Favor J, Neuhauser-Klaus A, Hrabe de Angelis M, Soewarto D, Moser A, Cordes S, Miller D, Chapman V et al. Effects of ENU dosage on mouse strains. Mammalian Genome 2000 11 484-488. (doi:10.1007/s003350010094) (Pubitemid 30602211)
59. Coghill EL, Hugill A, Parkinson N, Davison C, Glenister P, Clements S, Hunter J, Cox RD & Brown SD. A gene-driven approach to the identification of ENU mutants in the mouse. Nature Genetics 2002 30 255-256. (doi:10.1038/ng847)
60. Quwailid MM, Hugill A, Dear N, Vizor L, Wells S, Horner E, Fuller S, Weedon J, McMath H, Woodman P et al. A gene-driven ENU-based approach to generating an allelic series in any gene. Mammalian Genome 2004 15 585-591. (doi:10.1007/s00335-004-2379-z) (Pubitemid 39050021)
61. Barbaric I, Wells S, Russ A & Dear TN. Spectrum of ENUinduced mutations in phenotype-driven and gene-driven screens in the mouse. Environmental and Molecular Mutagenesis 2007 48 124-142. (doi:10.1002/em.20286) (Pubitemid 46365329)
62. Spyroglou A, Wagner S, Gomez-Sanchez C, Rathkolb B, Wolf E, Manolopoulou J, Reincke M, Bidlingmaier M, Hrabe de Angelis M & Beuschlein F. Utilization of a mutagenesis screen to generate mouse models of hyperaldosteronism. Endocrinology 2011 152 326-331. (doi:10.1210/en.2010-1081)
63. Born-Frontsberg E, Reincke M, Rump LC, Hahner S, Diederich S, Lorenz R, Allolio B, Seufert J, Schirpenbach C, Beuschlein F et al. Cardiovascular and cerebrovascular comorbidities of hypokalemic and normokalemic primary aldosteronism: results of the German Conn's registry. Journal of Clinical Endocrinology and Metabolism 2009 94 1125-1130. (doi:10.1210/jc.2008-2116)
64. Reincke M, Rump LC, Quinkler M, Hahner S, Diederich S, Lorenz R, Seufert J, Schirpenbach C, Beuschlein F, Bidlingmaier M et al. Risk factors associated with a low glomerular filtration rate in primary aldosteronism. Journal of Clinical Endocrinology and Metabolism 2009 94 869-875. (doi:10.1210/jc.2008- 1851)
65. Betz MJ, Degenhart C, Fischer E, Pallauf A, Brand V, Linsenmaier U, Beuschlein F, Bidlingmaier M & Reincke M. Adrenal vein sampling using rapid cortisol assays in primary aldosteronism is useful in centers with low success rates. European Journal of Endocrinology 2011 165 301-306. (doi:10.1530/EJE-11- 0287)
66. Vonend O, Ockenfels N, Gao X, Allolio B, Lang K, Mai K, Quack I, Saleh A, Degenhart C, Seufert J et al. Adrenal venous sampling: evaluation of the German Conn's registry. Hypertension 2011 57 990-995. (doi:10.1161/HYPERTENSIONAHA. 110.168484)
67. Reincke M, Fischer E, Gerum S, Merkle K, Schulz S, Pallauf A, Quinkler M, Hanslik G, Lang K, Hahner S et al. Observational study mortality in treated primary aldosteronism: the German Conn's registry. Hypertension 2012 60 618-624. (doi:10.1161/HYPERTENSIONAHA.112.197111)
68. Johnsen IK, Hahner S, Briere JJ, Ozimek A, Gimenez-Roqueplo AP, Hantel C, Adam P, Bertherat J & Beuschlein F. Evaluation of a standardized protocol for processing adrenal tumor samples: preparation for a European Adrenal Tumor Bank. Hormone and Metabolic Research 2010 42 93-101. (doi:10.1055/s-0029- 1241858)
69. Fassnacht M, Johanssen S, Quinkler M, Bucsky P, Willenberg HS, Beuschlein F, Terzolo M, Mueller HH, Hahner S & Allolio B. Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a Revised TNM Classification. Cancer 2009 115 243-250. (doi:10.1002/cncr.24030)
70. Stell A, Sinnott R & Jiang J. Enabling secure, distributed collaborations for adrenal tumor research. Studies in Health Technology and Informatics 2010 159 259-263.
71. Hannemann A, Bidlingmaier M, Friedrich N, Manolopoulou J, Spyroglou A, Volzke H, Beuschlein F, Seissler J, Rettig R, Felix SB et al. Screening for primary aldosteronism in hypertensive subjects: results from two German Epidemiological Studies. European Journal of Endocrinology 2012 167 7-15. (doi:10.1530/EJE-11-1013)
72. Newton-Cheh C, Guo CY, Gona P, Larson MG, Benjamin EJ, Wang TJ, Kathiresan S, O'Donnell CJ, Musone SL, Camargo AL et al. Clinical and genetic correlates of aldosterone-to-renin ratio and relations to blood pressure in a community sample. Hypertension 2007 49 846-856. (doi:10.1161/01.HYP.0000258554. 87444.91) (Pubitemid 351664212)
73. Alvarez-Madrazo S, Padmanabhan S, Mayosi BM, Watkins H, Avery P,Wallace AM, Fraser R, Davies E, Keavney B & Connell JM. Familial and phenotypic associations of the aldosterone Renin ratio. Journal of Clinical Endocrinology and Metabolism 2009 94 4324-4333. (doi:10.1210/jc.2009-1406)
74. Frazer KA, Ballinger DG, Cox DR, Hinds DA, Stuve LL, Gibbs RA, Belmont JW, Boudreau A, Hardenbol P, Leal SM et al. A second generation human haplotype map of over 3.1 million SNPs. Nature 2007 449 851-861. (doi:10.1038/nature06258) (Pubitemid 47598626)
75. Hirschhorn JN & Daly MJ. Genome-wide association studies for common diseases and complex traits. Nature Reviews. Genetics 2005 6 95-108. (doi:10.1038/nrg1521) (Pubitemid 40179532)
76. Ehret GB, Munroe PB, Rice KM, Bochud M, Johnson AD, Chasman DI, Smith AV, Tobin MD, Verwoert GC, Hwang SJ et al. Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature 2011 478 103-109. (doi:10.1038/nature10405)
77. Lifton RP, Dluhy RG, Powers M, Rich GM, Cook S, Ulick S & Lalouel JM. A chimaeric 11β-hydroxylase/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension. Nature 1992 355 262-265. (doi:10.1038/355262a0)
78. Iida A, Blake K, Tunny T, Klemm S, Stowasser M, Hayward N, Gordon R, Nakamura Y & Imai T. Allelic losses on chromosome band 11q13 in aldosterone-producing adrenal tumors. Genes,Chromosomes & Cancer 1995 12 73-75. (doi:10.1002/gcc.2870120114)
79. Pareek CS, Smoczynski R & Tretyn A. Sequencing technologies and genome sequencing. Journal of Applied Genetics 2011 52 413-435. (doi:10.1007/s13353-011-0057-x)
80. Choi M, Scholl UI, Yue P, Bjorklund P, Zhao B, Nelson-Williams C, JiW, Cho Y, Patel A, Men CJ et al. KC channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension. Science 2011 331 768-772. (doi:10.1126/science.1198785)
81. Boulkroun S, Beuschlein F, Rossi GP, Golib-Dzib JF, Fischer E, Amar L, Mulatero P, Samson-Couterie B, Hahner S, Quinkler M et al. Prevalence, clinical, and molecular correlates of KCNJ5 mutations in primary aldosteronism. Hypertension 2012 59 592-598. (doi:10.1161/HYPERTENSIONAHA.111.186478)
82. Barreau O, Assie G, Wilmot-Roussel H, Ragazzon B, Baudry C, Perlemoine K, Rene-Corail F, Bertagna X, Dousset B, Hamzaoui N et al. Identification of a CpG island methylator phenotype in adrenocortical carcinomas. Journal of Clinical Endocrinology and Metabolism 2013 98 E174-E184. (doi:10.1210/jc.2012-2993)
83. Xekouki P, Hatch MM, Lin L, Rodrigo de A, Azevedo M, de la Luz Sierra M, Levy I, Saloustros E, Moraitis A, Horvath A et al. KCNJ5 mutations in the National Institutes of Health cohort of patients with primary hyperaldosteronism: an infrequent genetic cause of Conn's syndrome. Endocrine-Related Cancer 2012 19 255-260. (doi:10.1530/ERC-12-0022)
84. Beuschlein F, Boulkroun S, Osswald A, Wieland T, Nielsen HN, Lichtenauer UD, Penton D, Schack VR, Amar L, Fischer E et al. Somatic mutations in ATP1A1 and ATP2B3 lead to aldosteroneproducing adenomas and secondary hypertension. Nature Genetics 2013 45 440-444. (doi:10.1038/ng.2550)
85. Akerstrom T, Crona J, Delgado Verdugo A, Starker LF, Cupisti K, Willenberg HS, Knoefel WT, Saeger W, Feller A, Ip J et al. Comprehensive re-sequencing of adrenal aldosterone producing lesions reveal three somatic mutations near the kcnj5 potassium channel selectivity filter. PLoS ONE 2012 7 e41926. (doi:10.1371/journal.pone.0041926)
86. Azizan EA, Murthy M, Stowasser M, Gordon R, Kowalski B, Xu S, Brown MJ & O'Shaughnessy KM. Somatic mutations affecting the selectivity filter of KCNJ5 are frequent in 2 large unselected collections of adrenal aldosteronomas. Hypertension 2012 59 587-591. (doi:10.1161/HYPERTENSIONAHA.111.186239)
87. Monticone S, Hattangady NG, Nishimoto K, Mantero F, Rubin B, Cicala MV, Pezzani R, Auchus RJ, Ghayee HK, Shibata H et al. Effect of KCNJ5 mutations on gene expression in aldosteroneproducing adenomas and adrenocortical cells. Journal of Clinical Endocrinology and Metabolism 2012 97 E1567-E1572. (doi:10.1210/jc.2011-3132)
88. Azizan EA, Lam BY, Newhouse SJ, Zhou J, Kuc RE, Clarke J, Happerfield L, Marker A, Hoffman GJ & Brown MJ. Microarray, qPCR, and KCNJ5 sequencing of aldosterone-producing adenomas reveal differences in genotype and phenotype between zona glomerulosa- and zona fasciculata-like tumors. Journal of Clinical Endocrinology and Metabolism 2012 97 E819-E829. (doi:10.1210/jc.2011-2965)
89. Taguchi R, Yamada M, Nakajima Y, Satoh T, Hashimoto K, Shibusawa N, Ozawa A, Okada S, Rokutanda N, Takata D et al. Expression and mutations of KCNJ5 mRNA in Japanese patients with aldosterone-producing adenomas. Journal of Clinical Endocrinology and Metabolism 2012 97 1311-1319. (doi:10.1210/jc.2011-2885)